Senzime AB (SEZI) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.081x

Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-23.03 Million ≈ $-2.48 Million USD) by net assets (Skr283.50 Million ≈ $30.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SEZI stock market capitalisation for the company's overall valuation and market capitalisation.

Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Senzime AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency. See debt repayment capacity of Senzime AB to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
Latitude Tree Holdings Bhd
KLSE:7006
0.021x
Shareholder Value Beteiligungen AG
XETRA:SVE
0.043x
Deswell Industries Inc
NASDAQ:DSWL
0.027x
Unick Corporation
KQ:011320
0.105x
Aarti Surfactants Limited
NSE:AARTISURF
0.091x
Innventure, Inc.
NASDAQ:INV
-0.050x
Southern Rubber Industry JSC
VN:CSM
0.143x
Zegona Communications Plc
LSE:ZEG
-0.535x

Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)

The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. View Senzime AB stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr304.46 Million
≈ $32.76 Million
Skr-109.10 Million
≈ $-11.74 Million
-0.358x -16.98%
2024-12-31 Skr345.86 Million
≈ $37.22 Million
Skr-105.94 Million
≈ $-11.40 Million
-0.306x -0.97%
2023-12-31 Skr375.48 Million
≈ $40.41 Million
Skr-113.91 Million
≈ $-12.26 Million
-0.303x +41.91%
2022-12-31 Skr261.90 Million
≈ $28.18 Million
Skr-136.78 Million
≈ $-14.72 Million
-0.522x +3.31%
2021-12-31 Skr150.58 Million
≈ $16.20 Million
Skr-81.33 Million
≈ $-8.75 Million
-0.540x -225.94%
2020-12-31 Skr231.35 Million
≈ $24.90 Million
Skr-38.34 Million
≈ $-4.13 Million
-0.166x +0.04%
2019-12-31 Skr163.69 Million
≈ $17.62 Million
Skr-27.14 Million
≈ $-2.92 Million
-0.166x -56.49%
2018-12-31 Skr167.41 Million
≈ $18.02 Million
Skr-17.73 Million
≈ $-1.91 Million
-0.106x -21.04%
2017-12-31 Skr140.46 Million
≈ $15.12 Million
Skr-12.29 Million
≈ $-1.32 Million
-0.088x -15.36%
2016-12-31 Skr131.87 Million
≈ $14.19 Million
Skr-10.00 Million
≈ $-1.08 Million
-0.076x +45.81%
2015-12-31 Skr45.81 Million
≈ $4.93 Million
Skr-6.41 Million
≈ $-690.18K
-0.140x -60.40%
2014-12-31 Skr44.08 Million
≈ $4.74 Million
Skr-3.85 Million
≈ $-414.05K
-0.087x +39.78%
2013-12-31 Skr37.46 Million
≈ $4.03 Million
Skr-5.43 Million
≈ $-584.31K
-0.145x +23.55%
2012-12-31 Skr31.99 Million
≈ $3.44 Million
Skr-6.06 Million
≈ $-652.57K
-0.190x -170.80%
2011-12-31 Skr27.87 Million
≈ $3.00 Million
Skr-1.95 Million
≈ $-209.94K
-0.070x +27.67%
2010-12-31 Skr21.90 Million
≈ $2.36 Million
Skr-2.12 Million
≈ $-228.10K
-0.097x -0.30%
2009-12-31 Skr16.61 Million
≈ $1.79 Million
Skr-1.60 Million
≈ $-172.54K
-0.096x -664.63%
2006-12-31 Skr7.55 Million
≈ $812.29K
Skr129.00K
≈ $13.88K
0.017x --

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$49.06 Million
Skr455.92 Million SEK
Market Cap Rank
#22050 Global
#407 in Sweden
Share Price
Skr2.90
Change (1 day)
+0.87%
52-Week Range
Skr2.88 - Skr6.59
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more